Serendipity: Werner's argument that the `two-only forms' (green and violet) of [CoCl(en)] salts demanded his octahedral model was correct. True?

Acta Crystallogr C Struct Chem

Carl A. Olson Memorial Laboratories, Department of Chemistry, Rutgers University, 73 Warren St., Newark, NJ 07102, USA.

Published: March 2020

Chemists of the late 19th century, including Alfred Werner, prepared salts containing either green or violet cations of composition [CoCl(en)] (en is ethylenediamine, CHN); we now refer to these as trans-dichloro and cis-dichloro species. We have discovered a third salt, purple in color, containing cations of the same elemental composition and whose asymmetric unit composition is [CoCl(en)]Cl·3HO, in which the cobalt cations are a cis:trans dichloro pair. Such a discovery would undermine Werner's argument that if only two forms can be prepared, his octahedral theory was proven. Probably because his students never examined their crystals under a microscope, they failed to observe the `third' species, thereby ruining Werner's argument since he relied strictly on color to identify them. That was fortunate since our purple salt would have led him to abandon, or certainly delay, his momentous discovery. Our crystals consist of a 1:1 mixture of the cis and trans cations, thereby sharing the same elemental analysis and conductivity as the single salts, but not their crystal structure, inasmuch as X-ray diffraction had not even been discovered then. Serendipitously, our discovery would have been a great boon to his theoretical acumen, while his `two-color' argument may have doomed him.

Download full-text PDF

Source
http://dx.doi.org/10.1107/S2053229620002272DOI Listing

Publication Analysis

Top Keywords

werner's argument
12
green violet
8
serendipity werner's
4
argument
4
argument `two-only
4
`two-only forms'
4
forms' green
4
violet [coclen]
4
[coclen] salts
4
salts demanded
4

Similar Publications

Background: The integration of connected medical devices (MDs) into health care brings benefits but also introduces new, often challenging-to-assess risks related to cybersecurity, which have the potential to harm patients. Current regulations in the European Union and the United States mandate the consideration of these risks in the benefit-risk analysis (BRA) required for MD approval. This important step in the approval process weighs all the defined benefits of a device with its anticipated risks to ensure that the product provides a positive argument for use.

View Article and Find Full Text PDF

Objective: Women with or at risk of hereditary breast- and ovarian cancer (HBOC) often live a surveillance-focused life from young adulthood. As they navigate a life of heightened medical vigilance, or a "cancer surveillance life," we explore how women with HBOC, as well as their partners and families, experience this particular kind of living through a thorough literature review of existing qualitative research.

Methods: We performed Boolean searches in PubMed, EMBASE, EBSCOhost, PSYCHinfo, Scopus, and Web of Science from April-May 2022, identifying 506 relevant articles.

View Article and Find Full Text PDF

Cardinal Composition.

Erkenntnis

July 2022

Institut für Philosophie, Universität Bern, Länggassstrasse 49a, 3012 Bern, Switzerland.

The thesis of Weak Unrestricted Composition says that every pair of objects has a fusion. This thesis has been argued by Contessa (Analysis 72(3):455-457, 2012) and Smith (Erkenntnis 84(1):41-55, 2019) to be compatible with the world being junky and hence to evade an argument against the necessity of Strong Unrestricted Composition proposed by Bohn (Analysis 69(1):27-31, 2009a, Philos Q 59(235):193-201, 2009b). However, neither Weak Unrestricted Composition alone nor the different variants of it that have been proposed in the literature can provide us with a satisfying answer to the special composition question, or so we will argue.

View Article and Find Full Text PDF

Molecular and Phenotypic Characterization of the -Related Disorder.

Neurology

January 2024

From the Department of Pediatric Clinical Epileptology (Z.G.-S., J.D.B., A.A.A.), Sleep Disorders and Functional Neurology, University Hospitals of Lyon, HCL, Member of ERN Epicare, France; Neuroscience Department (A.V., T.P., R.G.) IRCCS, Children's Hospital Meyer, Member of ERN Epicare, and University of Florence, Italy; Univ Lyon (L.M., N.P., D.S., N.C., J.C., G.L.), Univ Lyon 1, CNRS, INSERM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, U1315, Institut NeuroMyoGène, France; Pediatric Neurology Unit (C.M.K., J.F.), University Hospitals of Geneva, Switzerland; Child Neurology and Psychiatric Unit (C.M., E.C.), Children's Hospital G. Salesi, Azienda Universitaria Ospedaliera delle Marche, Ancona, Italy; Department of Neurology (B.M.A.), University Hospitals of Montpellier; Department of Genetics (D.S., N.C., A. Labalme, G.L.), University Hospitals of Lyon, HCL, Member of ERN Epicare, France; Paediatric Epilepsy Research (A.A.A.), Child Neurology Department, Member of the ERN EpiCARE, San Juan de Dios Children's Hospital, Barcelona, Spain; Division of Neurology (V.A.C., S.M.R., I.H.), and The Epilepsy NeuroGenetics Initiative (ENGIN) (V.A.C., S.M.R., K.L.H., I.H.), Children's Hospital of Philadelphia, PA; Department of Neurology (V.A.C., S.M.R., I.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Univ Rouen Normandie (F.L., G.N.), Inserm U1245 and CHU Rouen, Department of Genetics and Reference Center for Developmental Disorders; Department of Pediatric Neurology (G.A.M., A. Lebas), University Hospitals of Rouen; Department of Pediatric Neurology (H.O.T.), Hospital of Alpes Léman, Annemasse, France; Department of Pediatric Neurology (A.R.), Barcelona Children's Hospital, University of Barcelona, Spain; Developmental Neurosciences (A.N., M.A.K., K.R., R.S.), Zayed Centre for Research, University College of London, Great Ormond Street Hospital, Institute of Child Health, United Kingdom; Institute of Medical Genetics (P.J.), University of Zürich; Department of Neuropediatrics (G. Ramantani, K.S.), University Children's Hospital and University of Zürich, Switzerland; Department of Neurology (M.K.), Medical University of Vienna, Austria; Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics (L.G.), Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Institute of Human Genetics (S.V.), Medical University of Innsbruck, Innsbruck, Austria; Werner-Forßmann-Krankenhaus (S.V., S.T.), Eberswalde, Germany; Pediatric Neurology Discipline (D.C.), Neurosciences Department, Carol Davila University of Medicine Bucharest; Pediatric Neurology Clinic (D.C.), Al Obregia Hospital, Center of Expertise for Pediatric Neurology Rare Disorders, Member of ERN EpiCARE, Bucharest, Romania; Institute of Clinical Molecular Biology (M.P., I.H.), Christian-Albrechts-University of Kiel, Germany; Mission Fullerton Genetics Center (C.H.-E.), Asheville, NC; Department of Neurology (I.K.), Svt. Luka's Institute of Child Neurology and Epilepsy, Moscow; Department of Medical Genetics (I.R.), Kazan State University, Russia; Division of Child Neurology (D.S.R.), Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, PA; Department of Molecular and Human Genetics (J.A.R.), Baylor College of Medicine, Houston, TX; Division of Clinical Genetics and Dysmorphology (M.A., K.G., J.M.G.), Cedars-Sinai Medical Center, Los Angeles, CA; Department of Neurology (A.I.), University Hospitals of Armand Trousseau, AP-HP, Paris; Department of Pediatric Neurology (N.V.), University Hospitals of Marseille, AP-HM; Univ. Lille (T.S.), CHU Lille, ULR7364, RADEME, Institute of Medical Genetics; Department of Clinical Genetics (R.C.), CHU Lille, France; Institute of Human Genetics (P.Z., S.N., K.P., T.B., I.M., M.R., R.A.J.), University of Leipzig Medical Center, Germany; Institute of Human Genetics (S.T.), Medical University of Innsbruck, Austria; Department of Biomedical and Health Informatics (DBHi) (I.H.), Children's Hospital of Philadelphia, PA; Department of Pediatric Neurology (F.E.J., K.K.), Brain Center UMC Utrecht, Member of ERN Epicare, Utrecht, the Netherlands; Department of Neurology (G. Rudolf), Strasbourg University Hospital; and Nantes Université (S.K.), CHU Nantes, Service de Génétique Médicale, and CNRS, INSERM, l'institut du thorax, France.

Background And Objectives: Heterozygous variants in RAR-related orphan receptor B () have recently been associated with susceptibility to idiopathic generalized epilepsy. However, few reports have been published so far describing pathogenic variants of this gene in patients with epilepsy and intellectual disability (ID). In this study, we aimed to delineate the epilepsy phenotype associated with pathogenic variants and to provide arguments in favor of the pathogenicity of variants.

View Article and Find Full Text PDF

Strong Supernova 1987A Constraints on Bosons Decaying to Neutrinos.

Phys Rev Lett

July 2023

Department of Physics and Astronomy, University of California, Los Angeles, California 90095-1547, USA.

Majoron-like bosons would emerge from a supernova (SN) core by neutrino coalescence of the form νν→ϕ and ν[over ¯]ν[over ¯]→ϕ with 100-MeV-range energies. Subsequent decays to (anti)neutrinos of all flavors provide a flux component with energies much larger than the usual flux from the "neutrino sphere." The absence of 100-MeV-range events in the Kamiokande-II and Irvine-Michigan-Brookhaven signal of SN 1987A implies that less than 1% of the total energy was thus emitted and provides the strongest constraint on the Majoron-neutrino coupling of g≲10^{-9}  MeV/m_{ϕ} for 100  eV≲m_{ϕ}≲100  MeV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!